Radotinib

Phase 3Small molecule

IIl-Yang Pharm. Co., Ltd.

Radotinib is one of 45 small molecule programs targeting Myeloid Leukemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myeloid LeukemiaActive, not recruiting

Myeloid LeukemiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

100 competitors in Myeloid Leukemia

#DrugCompanyPhaseTrials

Iclusig

Takeda

Phase 3

6 2

Trexall

Alnylam Pharmaceuticals

Phase 3

2 3

Xospata

Astellas

Phase 3

—4

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

39 5

Cytoxan

BBaxter Healthcare Corporation

Phase 3

1 6

Busulfex

Akero Therapeutics

Phase 3

1 7

Scemblix

Novartis

Phase 2

5 8

Actos

Takeda

Phase 2

3 9

Jakafi

Incyte

Phase 2

3 10

Cytosar

Teva

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Randomized1 trial

Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)

Active, not recruiting·IIl-Yang Pharm. Co., Ltd.·Phase 3·NCT03722420·238 enrolled

Myeloid Leukemia1 trial

Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients

Completed·IIl-Yang Pharm. Co., Ltd.·Phase 3·NCT01511289·242 enrolled

CML1 trial

Radotinib as 3rd or Later Line Therapy in CP-CML

Unknown status·UUlsan University Hospital·Phase 2·NCT02422719·73 enrolled

Philadelphia Chromosome Positive CML1 trial

Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI

Completed·IIl-Yang Pharm. Co., Ltd.·Phase 1/2·NCT01602952·85 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Radotinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Radotinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Radotinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Il-Yang Pharm. Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: IIl-Yang Pharm. Co., Ltd.

Radotinib

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Randomized1 trial

Myeloid Leukemia1 trial

CML1 trial

Philadelphia Chromosome Positive CML1 trial

References

Drug Info

Quick Facts

Related News